Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr 18:20:e00771.
doi: 10.1016/j.idcr.2020.e00771. eCollection 2020.

Guillain-Barré Syndrome associated with SARS-CoV-2 infection

Ahmed Virani  1 , Erica Rabold  1 , Taylor Hanson  2 , Aaron Haag  2 , Rawiya Elrufay  3 , Tariq Cheema  1 , Marvin Balaan  1 , Nitin Bhanot  3
Affiliations
Case Reports

Guillain-Barré Syndrome associated with SARS-CoV-2 infection

Ahmed Virani et al. IDCases. .

Abstract

We present a case of Guillain- Barré Syndrome (GBS) in a patient with confirmed COVID-19 infection. GBS in commonly encountered after an antecedent trigger, most commonly an infection. To date, only one case of GBS associated with this infection has been described. Clinicians should consider this entity since it may warrant appropriate isolation precautions especially in a patient who may not present primarily with typical constitutional and respiratory symptoms associated with COVID-19.

Keywords: COVID-19; Guillain-Barré Syndrome; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Tariq Cheema, MD is on the speaker’s bureau for Boehringer Ingelheim and Glaxo smith Kline.

References

    1. Holshue M.L., Debolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936. - PMC - PubMed
    1. Fokke C., van den Berg B., Drenthen J., Walgaard C., van Doorn P.A., Jacobs B.C. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43. - PubMed
    1. Coronavirus Cases: Worldometer. (n.d.). https://www.worldometers.info/coronavirus/ [Accessed 11 April 2020].
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. - PMC - PubMed
    1. Zhang C., Wu Z., Li J.W., Zhao H., Wang G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020 - PMC - PubMed

Publication types

LinkOut - more resources